Navigation Links
Reverse in Medical Technology

Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences

... Tibotec's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 ... of Truvada) in combination with a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor ... TMC278 is an investigational non-nucleoside reverse transcriptase inhibitor, and the safety and ...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

... is a combination product in the nucleoside(tide) reverse transcriptase inhibitor (NRTI) class. ... use two NRTIs with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ... 7 The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial ...

Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference

... Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with ... activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive ... About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential ...

BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union

... BRIDION allows anesthesiologists to rapidly reverse both moderate and deep ... it inactive. It was specifically designed to reverse within minutes both moderate and deep muscle ... pulmonary side effects. "The ability to rapidly reverse both moderate and deep levels of ...

Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing

... RDEA806, its novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with ... About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential ... is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has ...

Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting

... The second proposal related to the approval of a reverse stock split to be effected at a ratio of ten ... The shareholders of the Company approved the reverse stock split by the requisite vote. The Board of ... now authorized to set an effective date for the reverse stock split, and ...

European Union's CHMP Issues Positive Opinion on Sugammadex

... to rapidly and predictably reverse both moderate and deep muscle relaxation induced ... the end of a surgical procedure and to reverse the block in minutes. "This is an important ... clinical trials program. "The drug allows us to reverse the effects of rocuronium quickly and at the ...

Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients

... is a combination product in the nucleoside reverse transcriptase inhibitor (NRTI) class. "A ... use two NRTIs with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or ... 9 The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of ...

Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load

... RDEA806, its novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with ... About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential ... candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a ...

FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent

... Recommends FDA Approve Novel Anesthesia Drug to reverse Muscle relaxation within ... the ability to rapidly and predictably reverse any depth of muscle relaxation induced by ... options. Sugammadex is specifically designed to reverse the effects of certain widely used muscle ...

Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes

... (HDL), that creates a defect in reverse cholesterol transport in patients with Diabetes ... product to decrease HDL oxidation and restore reverse cholesterol transport function," said ... a mechanistic explanation for the defect in reverse cholesterol transport observed in many patients ...

New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation

... function of the left ventricle (commonly known as reverse remodeling), according to data presented this ... of Echocardiography guidelines. Significant reverse Remodeling of the Left Ventricle -- 12 months after a successful MitraClip procedure, significant reverse remodeling of the left ventricle was ...

Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia

... neuromuscular, and be able to reverse the blockade rapidly at any moment they want, ... agents are used during general anesthesia to reverse the effects of muscle relaxants, also called ... sugammadex has demonstrated the ability to reverse shallow and profound depths of rocuronium-induced ...

Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC

... against the majority of HIV strains carrying key reverse transcriptase mutations, including coverage ... About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential ... RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment ...

Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806

... in Hall D. -- "RDEA806, a Potent Non-Nucleoside reverse Transcriptase Inhibitor with Less Potential ... About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential ... RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment ...

Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)

... chronic tension in the jaw, face, neck and upper back. The lessons also reverse long-standing movement habits often responsible for the original TMJ ... Movement Institute, designed the Intelligent Body(R) TMJ Program to help reverse many people's longstanding habits that create tension and stress and ...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

... - Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to reverse the Immune Suppressing Effects of Tumors by Changing the Tumor ... destroy the blood vessels supporting tumor growth and spread and also to reverse the ability of tumors to suppress the body's natural immune response, ...

Aching Back? Cholesterol Medication Might Help

... medicine cabinet. In their quest to discover ways to stop or reverse degenerative disc disease, orthopaedic researchers have been removing disc ... stage of intervertebral disc degeneration can theoretically retard or even reverse the degenerative process and possibly regain a healthy intervertebral ...

Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV

... exclusive worldwide rights to IDX899. IDX899 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development being ... conditions. About IDX899 IDX899 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of ....

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... relevant instances, such as prior to surgery, when there is the need to reverse the effects of an anticoagulant. The reversal of the anticoagulant effect ... infusion of avidin (100 mg), a hen egg protein that binds with biotin to reverse the Factor Xa inhibiting activity of idrabiotaparinux. At the end of the ...

Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients

... a potential opportunity to preserve nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs), integrase inhibitors, fusion ... J Med 2007; 356: 1723-35. (10) The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected ...

Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594

... with hyperuricemia. RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. ... Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the ...

Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results

... positive preliminary results for RDEA806, our lead non- nucleoside reverse transcriptase inhibitor (NNRTI), in a Phase 2a monotherapy study in ... discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the ...

CureDM's Diabetes Therapy Achieves Major Development Milestone

... company developing new therapies that prevent, ameliorate, or reverse both type 1 and 2 diabetes, announces its achievement of a major drug ... new insulin-producing cells through islet neogenesis can potentially reverse both type 1 and type 2 diabetes. Patients with type 1 diabetes will ...

ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests

... acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) that is being developed to provide benefits ... acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) that is being developed to provide benefits ...

Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights

... have been retroactively adjusted to account for the effect of a 1-for-6 reverse stock split on July 13, 2007.) Net product sales of $0.3 million for the ... computing basic and diluted net loss per share (adjusted for 1-for-6 reverse stock split on July 13, 2007) 30,621 25,621 29,621 ...

Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.

... agreements with Gilead Sciences to develop tenofovir (PMPA), a nucleoside reverse transcriptase inhibitor. In October 2005, IPM entered agreements with ... subsidiary Tibotec Pharmaceuticals to develop the company's non-nucleoside reverse transcriptase inhibitor, dapivirine, as a microbicide; IPM expects to put ...

Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus

... of this year as well. About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV ... most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the ...

ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference

... profile for ANX-201 that suggests suppression of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class of drugs. The ... acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) for treatment of resistant HIV-infected ...

Genta Incorporated Announces Third Quarter 2007 Financial Results

... have been retroactively adjusted to account for the effect of a 1-for-6 reverse stock split on July 13, 2007.) Net product sales of Ganite were $0.1 ... computing basic and diluted net loss per share (adjusted for 1-for-6 reverse stock split on July 13, 2007) 30,621 22,598 29,284 ...

Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients

... and Prevention; July 2007; Sydney, Australia. 2 NRTI - nucleoside reverse transcriptase inhibitor 3 NNRTI - non-nucleoside reverse transcriptase inhibitor 4 PI - protease inhibitor ...

A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol

... animal models of cancer and human cell lines, phenoxodiol was shown to reverse chemoresistance to standard chemotherapies, including platinum drugs, taxanes, gemcitabine, topotecan and doxorubicin. The ability of phenoxodiol to reverse multi-drug resistance is thought to be due to its disruption of several ...

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

... disease and Mild Cognitive Impairment, the precursor to Alzheimer's. These studies indicate that blocking the effects of this protein may halt or reverse Alzheimer's disease. Cognition will use these funds to test its most promising lead molecules in behavioral models of Alzheimer's disease. "The ...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

... demonstrated broad activity as a single agent; synergy with commonly used chemotherapy agents, targeted agents, and radiation; and has been shown to reverse resistance mediated through the PI3K/PTEN pathway. About PI3 Kinase Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major ...

Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

... represents a common pathway resulting in a defect in the ability of the heart to contract properly. Replacing the enzyme may restore function and reverse heart failure. The Phase 2 randomized, double-blind, placebo-controlled, parallel-group, dose ranging portion of the study is designed to ...

Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)

... is a privately held company founded in 2006. Its proprietary technology platform includes fixative reagents, Laser Capture Microdissection (LCM), and reverse Phase Protein Microarray (RPMA). TH's proprietary fixatives are developed to both preserve cell morphology and fix the state of cellular activities ...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

... demonstrated broad activity as a single agent; synergy with commonly used chemotherapy agents, targeted agents, and radiation; and has been shown to reverse resistance mediated through the PI3K/PTEN pathway. About PI3 Kinase Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major ...

Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan

... in adult life. Results of the study suggest that oral and topical AC-11(R) products, when combined, are an inner and outer beauty solution to help reverse the signs of premature aging. The French research, which was sponsored by Itochu, compliments earlier published third party studies ...

Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease

... According to lead author, Michel F. Levesque, MD, FRCS(C), FACS, "We have documented the first successful adult neural stem cell transplantation to reverse the effects of Parkinson's disease and demonstrated the long term safety and therapeutic effects of this approach." Dr Levesque is a principal ...

Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)

... without metabolic rebound, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation. About Genaera Genaera Corporation is ...
Other Contents
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
(Date:9/1/2015)... ... 01, 2015 , ... OncLive® today announced it ... & World Report, to provide breaking news and information about the hospital’s pioneering ... OncLive, which provides oncologists resources and information?they need to deliver the best care ...
(Date:9/1/2015)... ... 2015 , ... The Jerry Segal Classic to benefit the patients of Magee ... Club in Lafayette Hill, PA. Over the past 26 years, the Classic, organized by ... services designed to support patients and their families during their time at Magee Rehabilitation ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among ... Math) disciplines since its inception more than 35 years ago. A pilot program begun ... their teachers - and, not just those intent on pursuing careers in these fields. ...
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 ... ... solutions, today announced the release of version 5.2 of the FirstSpirit Content Management ... Content Cloud initiative. With the new version of FirstSpirit, companies will be well ...
(Date:9/1/2015)... ... 2015 , ... Zecurion, a leading developer of data loss prevention solutions, announced ... DLP developed specifically for Mac OS. , In June 2015, the company successfully completed ... security professionals had participated. The beta test done by the developer community enabled Zecurion ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2
Other TagsOther Tags